Therapeutic vaccination with papillomavirus E6 and E7 long peptides results in the control of both established virus-induced lesions and latently infected sites in a pre …
A Vambutas, J DeVoti, M Nouri, JW Drijfhout… - Vaccine, 2005 - Elsevier
A Vambutas, J DeVoti, M Nouri, JW Drijfhout, GB Lipford, VR Bonagura, SH Van der Burg…
Vaccine, 2005•ElsevierThis study was performed to test the therapeutic efficacy of overlapping long E6 and E7
peptides, containing both CD4+ T-helper and CD8+ CTL epitopes, on CRPV-induced
lesions, which is an appropriate pre-clinical model for HPV diseases, including recurrent
respiratory papillomatosis (RRP). Therapeutic peptide vaccination was able to significantly
control wart growth (p< 0.01) and abrogate latent CRPV infection (p= 0.0006) compared to
controls. Vaccination was associated with a TH1 T cell response, as suggested by a strong …
peptides, containing both CD4+ T-helper and CD8+ CTL epitopes, on CRPV-induced
lesions, which is an appropriate pre-clinical model for HPV diseases, including recurrent
respiratory papillomatosis (RRP). Therapeutic peptide vaccination was able to significantly
control wart growth (p< 0.01) and abrogate latent CRPV infection (p= 0.0006) compared to
controls. Vaccination was associated with a TH1 T cell response, as suggested by a strong …
This study was performed to test the therapeutic efficacy of overlapping long E6 and E7 peptides, containing both CD4+ T-helper and CD8+ CTL epitopes, on CRPV-induced lesions, which is an appropriate pre-clinical model for HPV diseases, including recurrent respiratory papillomatosis (RRP). Therapeutic peptide vaccination was able to significantly control wart growth (p<0.01) and abrogate latent CRPV infection (p=0.0006) compared to controls. Vaccination was associated with a TH1 T cell response, as suggested by a strong DTH skin test, antigen-specific proliferation of PBMC and a minimal IgG antibody response. Thus, this study shows promise for treatment of RRP by vaccination with long peptides.
Elsevier